Replimune REPL 深 沪
等待开盘 10-07 09:30:00 美东时间
13.25
+0.100
+0.76%
华盛通- 最 高13.51
- 今 开13.17
- 成交量 261.80万股
- 最 低 12.87
- 昨 收 13.15
- 总市值 12.48亿
- 52周最高 16.33
- 市盈率 静 --
- 换手率 2.78%
- 52周最低 1.50
- 委 比 -66.10%
- 总股本 9421.96万
- 历史最高 54.79
- 量 比 0.97
- 振 幅 4.87%
- 历史最低 1.50
- 每 手 1
- 风险率 3.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Replimune Group Announces Commercial Availability Of TUDRIQEV In U.S. To Treat Unresectable Advanced Cutaneous Melanoma
Replimune Group, Inc. (NASDAQ:REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that TUDRIQEV™ (vusolimogene oderparepvec-wtpg) is now commercially available in the United States. TUDRIQEV is indicated in combination with n...
10-02 04:02
Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma
Replimune Group, Inc. announced the commercial availability of TUDRIQEV™ (vusolimogene oderparepvec-wtpg) in the U.S. for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a PD-1-blocking antibody-based regimen. TUDRIQEV is approved under accelerated approval based on objective response rate and duration of response, and is administered via intratumor injection in combination wi...
10-01 20:01
Replimune to Present at the Cantor Global Healthcare Conference 2026
Replimune Group, Inc. announced that its management team will participate in a fireside chat at the Cantor Global Healthcare Conference on September 10, 2026, at 9:10 AM ET. A webcast will be available on Replimune’s website, with a replay accessible for 30 days. Replimune, headquartered in Woburn, MA, focuses on developing novel oncolytic immunotherapies, including TUDRIQEV, approved for advanced melanoma treatment. The company’s RPx platform us...
09-03 12:00
美股大行评级 | 潜在涨幅1849.95%！Ascendiant Capital上调IGC Pharma目标价至6美元，维持"买入"评级；迪克体育、财捷遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.5美元升至6美元；Ascendiant Capital：维持Quantum Computing"买入"评级，目标价从30美元升至32美元
08-27 08:37
Replimune Group Lawsuit Focuses on FDA Disclosure Issues and Sharp REPL Stock Drop
ReplimuneGroup, Inc. (NASDAQ: REPL) is facing a federal securities lawsui...
08-22 03:13
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Replimune Group granted inducement equity awards to Michelle DiNapoli, including 150,000 stock options and 100,000 restricted stock units, vesting over four years. The awards were approved under Nasdaq Listing Rule 5635(c)(4) and align with the 2018 Equity Incentive Plan. Replimune, a biotech company, focuses on developing oncolytic immunotherapies, with its lead product TUDRIQEV approved for advanced melanoma treatment.
08-19 20:01
财报速睇 | Replimune 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损0.70亿美元，同比亏损缩窄19.5%
华盛资讯8月15日讯，Replimune公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损0.70亿美元，同比亏损缩窄19.5%。
08-15 05:22
Replimune Group Files Shelf Prospectus For Offering; Size Not Disclosed
Replimune Group Files Shelf Prospectus For Offering; Size Not Disclosed
08-15 04:55
财报速睇 | Replimune 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损0.70亿美元，同比亏损缩窄19.5%
华盛资讯8月14日讯，Replimune公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损0.70亿美元，同比亏损缩窄19.5%。
08-14 20:32
Replimune Group Q1 EPS $(0.72) Beats $(0.73) Estimate
Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.73) by 1.37 percent. This is a 24.21 percent increase over losses of $(0.95) per share from the same period last year.
08-14 20:06
